Press Releases | 3 November 2020

Health Canada Approves Canada’s First HIV Self Test

Made-In-Canada INSTI® HIV Self Test Provides Results in 1 Minute and is More Than 99% Accurate


Read More »

News | 11 November 2020

INSTI in the News: HIV Self Test Comes to Canada

INSTI HIV Self Test brings easy, fast and reliable at-home HIV testing to Canadians.

Read More »

News | 5 June 2020

INSTI SARS-Cov-2 Antibody Test in the News

We recently announced the development of our new INSTI SARS-CoV-2 Antibody Test. Based on the 1-minute INSTI platform, the test will detect antibodies to SARS-CoV-2, the virus that causes COVID-19. We have been supported by the government’s NRC IRAP, which has provided advice and financial resources to Canadian companies for more than 70 years, helping them bring innovative ideas to market. When completed, the test will be a helpful tool for supporting the medical community in monitoring the spread of the virus.

Our scientists are still hard at work developing the test, but our Chief Scientific Officer, Michelle Zaharik took some time out of her busy schedule to speak to journalists about this exciting news in these articles:

Daily Hive: BC company receives over $600K to develop one-minute coronavirus antibody test
Business in Vancouver: B.C. biotech taps federal funding for 60-second COVID-19 test
Prince George Matters: B.C. biotech taps federal funding for 60-second COVID-19 test
360dx: Biolytical Awarded C$633K to Develop One-Minute COVID-19 Antibody Test
BioWorld: Roundup for May 27, 2020

Read More »

  • bioLytical® Laboratories develops and manufactures a rapid HIV diagnostic product, the INSTI® Kit. It is a unique, simple-to-use diagnostic kit used in the diagnosis of HIV infection. At 60 seconds for a reading, INSTI® Kit is the fastest HIV diagnostic assay in the world today. The INSTI® HIV-1/HIV-2 Antibody Test is a rapid in vitro qualitative test for the detection of antibodies to Human Immunodeficiency Virus Type 1 or Type 2 in human whole blood, fingerstick blood, or plasma.

  • You are currently viewing content for the Global region. Accept